FDA Grants T2 Biosystems Breakthrough Device Designation for the T2Resistance™ Panel; Expected Availability through CE Mark in 2019


You May Also Like

Type 2 Diabetes Trial Results Published In Diabetes Care

NEW YORK and MELBOURNE, Australia, July 22, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; ...

Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences

PLYMOUTH MEETING, Pa., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...